30 closest matches · ranked by relevance
Post-polio Syndrome · Physical Activity · Depression
Primary: PROMIS (Patient Reported Outcomes Measurement Information System) Physical Functioning — 37.8; 37.9; 37.5; 38.1 units on a scale — p=0.66
Acute Respiratory Failure
Primary: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 — 19.0; 20.9…
Stroke
Primary: Gait Speed — 0.51 meters per second
Parkinson's Disease · Multiple Sclerosis
Primary: Maximum Expiratory Pressure (MEP) — 78.6; 75.56; 99.00; 99.38 cm H2O — p=0.899
Progressive Supranuclear Palsy · Dementia With Lewy Bodies · Multiple System Atrophy
Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59
COVID-19 · Muscle Atrophy · Muscle Weakness
Primary: Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 363.04; 359.55 miliVolts
Respiration, Artificial · Critical Illness · Chronic Disease
Primary: Functional Assessment: Handgrip — 3.6; 1.3 kg
Stroke · Shoulder Pain
Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) - Mean Change From Baseline — 7.1; 7.4; 8.1; -2.8 units on a scale
Shoulder Pain · Shoulder Impingement Syndrome · Shoulder Tendinitis
Primary: Change in - Short Form (SF) Question 3 (BPI-SF3) — 6.90; 7.05; 3.58; 3.96 units on a scale
Post ICU Syndrome
Primary: Acceptance With COVID-19 Virtual Post Intensive Care Syndrome (CoV-PICS) Visits - AIM — 4.8 score on a scale
Chronic Obstructive Pulmonary Disease
Primary: Quadriceps Fibre Size of Type IIa Fibres — 3885; 4326; 3610 micrometers squared
Post COVID-19 Condition · Long COVID
Primary: Change From Baseline to Week 13 in PROMIS Fatigue Score (T-Score) — 69.9; 69.4; -25.4; -25.8 T-Score — p=0.9851
Pompe Disease
Primary: Inspiratory Load Compensation - Inspiratory Volume — 288.41; 554.34; 743.71; 927.57 mL
Postural Tachycardia Syndrome
Primary: C-peptide Levels After Oral Glucose Tolerance Test — 40.6; 23.2 pg/mL
Respiratory Failure
Primary: Level of Activity of Daily Life — 25.2; 32.0 units on a scale — p=0.652
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Post COVID Syndrome · Fatigue · Headache
Primary: Change in Post-COVID Functional Status Score — 0.1; 0.3 units on a scale — p=0.544
Spinal Cord Injuries
Primary: Acute Gene Regulation: MSTN — 5.49; 4.76 arbitrary units — p=<0.001
Post Thrombotic Syndrome · Deep Vein Thrombosis · Venous Stasis Syndrome
Primary: Median Optimal Electrical Stimulation Intensity Level for Largest Benefit in Relief of Symptoms — 32 mirco coulombs (0 to 50)
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome · Chronic Fatigue Syndrome · Myalgic Encephalomyelitis
Primary: Change in Peak Oxygen Uptake (Peak VO2) Between the First and Second iCPET — 13.3; -40.3; 111.8 mL/min — p=0.043
Covid19 · Muscle Atrophy · Muscle Weakness
Primary: Change in Gastrocnemius Muscle Endurance (Muscle Sustained Contraction) in Response to Electrical Stimulation — 352; 323 milliVolts
Stress Urinary Incontinence
Primary: Number of Participants Who Remain Continent or Improved Following Treatment Through 3 Months Follow-up — 26 Participants
Postural Orthostatic Tachycardia Syndrome
Primary: Change From Baseline to Week 24 in the COMPASS 31 (2-week Recall Version) — -14.369; -15.957 score on a scale
Parkinson's Disease · Drug-induced Parkinsonism
Primary: Change in Dopamine Transporter Imaging — 4.6; -15.9 % change in arbitrary intensity units
Albinism · Inborn Errors of Metabolism · Oculocutaneous Albinism
Primary: Change in Forced Vital Capacity (36 Months) — -23.52; -20.93 % of predicted volume
ALS
Primary: Standard PFT - Forced Vital Capacity — 72.7 Percent Predicted FVC
Postacute Sequelae of Sars-CoV-2 · Post-Acute COVID-19 Syndrome · Widespread Chronic Pain
Primary: Mean Change in Functional Interference From Pain From Baseline to 4 Weeks (Blinded Phase) — 0.454; 0.198 score on a scale
Covid19
Primary: Insulin-Like Growth Factor-1 (IGF1) — 142.8; 137.6 ng/ml
Chronic Post-stroke Headache
Primary: Change in Modified Rankin Scale From Baseline to Follow-up 30 Days After Last Intervention — 0; 1 units on a scale — p=0.896
Post-acute Covid-19 Syndrome
Primary: Fatigue Assessment Scale (FAS) — 32.9; 31.4; 29.0; 27.4 score on a scale